Goldman Sachs’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Goldman Sachs’s Portfolio FSTX Stock Details FSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-104,690	Closed	-$662K	–	6418
2022 Q4	$662K	Buy	104,690 +30,582	+41%	+$169K	﹤0.01%	4691
2022 Q3	$379K	Buy	74,108 +53,962	+268%	+$339K	﹤0.01%	5157
2022 Q2	$126K	Sell	20,146 -13,656	-40%	-$46K	﹤0.01%	5796
2022 Q1	$120K	Buy	+33,802	New	+$125K	﹤0.01%	6047
2019 Q3	–	Sell	-24,627	Closed	-$363K	–	5450
2019 Q2	$363K	Buy	+24,627	New	+$660K	﹤0.01%	4525
2018 Q3	–	Sell	-5,821	Closed	-$276K	–	5856
2018 Q2	$276K	Buy	5,821 +2,339	+67%	+$130K	﹤0.01%	4824
2018 Q1	$214K	Buy	+3,482	New	+$184K	﹤0.01%	4966
2017 Q2	–	Sell	-5,062	Closed	-$180K	–	7044
2017 Q1	$180K	Buy	+5,062	New	+$174K	﹤0.01%	5788

Goldman Sachs's FSTX Position: Q1 2023 in Review

Goldman Sachs sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q1 2023, closing a stake of 104,690 shares — an estimated $662K sold.

Goldman Sachs first reported a position in FSTX in Q1 2017 and held it in 8 quarters. The position peaked at $662K in Q4 2022. 0 funds tracked by Wall St. Rank hold FSTX as of Q1 2023.

Goldman Sachs reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Goldman Sachs sold 104,690 F-star Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $662K.
Goldman Sachs first reported a position in F-star Therapeutics, Inc. Common Stock in Q1 2017 and held it in 8 quarters.
Goldman Sachs's F-star Therapeutics, Inc. Common Stock position peaked at $662K in Q4 2022.
0 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.